II 

118TH CONGRESS 

1ST SESSION S. 2821 

To amend title XXVII of the Public Health Service Act to require group 

health plans and health insurance issuers offering group or individual 

health insurance coverage to provide coverage for prostate cancer 

screenings without the imposition of cost-sharing requirements, and for 

other purposes. 

IN THE SENATE OF THE UNITED STATES 

SEPTEMBER 14, 2023 

Mr. BOOKER (for himself and Mr. BOOZMAN) introduced the following bill; 

which was read twice and referred to the Committee on Health, Education, Labor, and Pensions 

A BILL 

To amend title XXVII of the Public Health Service Act 

to require group health plans and health insurance 

issuers offering group or individual health insurance coverage to provide coverage for prostate cancer screenings 

without the imposition of cost-sharing requirements, and 

for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•S 2821 IS

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Prostate-Specific Anti3 gen Screening for High-risk Insured Men Act’’ or the 

4 ‘‘PSA Screening for HIM Act’’. 

5 SEC. 2. FINDINGS. 

6 Congress finds the following: 

7 (1) Prostate cancer is the second leading cause 

8 of cancer death in men in the United States with 1 

9 in 41 men dying from prostate cancer and more 

10 than 34,700 men estimated to die from prostate 

11 cancer in 2023. 

12 (2) Prostate cancer is the second most com13 monly diagnosed cancer in the Nation with 1 in 8 

14 men being diagnosed in their lifetimes, 3.1 million 

15 men in the United States living with a diagnosis, 

16 and over 288,000 men estimated to be diagnosed in 

17 2023. 

18 (3) The survival rate for prostate cancer diag19 nosed in early stage is near 100 percent but prostate 

20 cancer diagnosed in late stage has only a 30-percent 

21 survival rate. 

22 (4) There are few, if any, symptoms of prostate 

23 cancer before it reaches late stage. 

24 (5) African-American men have a disproportion25 ately higher rate of prostate cancer and are 70 per26 cent more likely to be diagnosed with prostate canVerDate Sep 11 2014 05:11 Sep 15, 2023 Jkt 039200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\S2821.IS S2821

kjohnson on DSK7ZCZBW3PROD with $$_JOB
3 

•S 2821 IS

1 cer than White men, with 1 in 6 African-American 

2 men developing prostate cancer in their lifetimes. 

3 (6) African-American men are 2.1 times more 

4 likely to die from prostate cancer than White men. 

5 (7) Men with a father or brother with prostate 

6 cancer are more than twice as likely to be diagnosed 

7 with prostate cancer than men without a family his8 tory. 

9 (8) The common clinical definition for men at 

10 high-risk of prostate cancer includes African-Amer11 ican men and men with a family history. 

12 (9) Most of the major cancer and urological so13 cieties recommend beginning screening discussions 

14 earlier for African-American men and those with a 

15 family history of prostate cancer. 

16 (10) The United States Preventive Services 

17 Task Force has encouraged research on screening 

18 African-American men, including whether to screen 

19 African-American men at younger ages, and has 

20 identified this research as a high-priority cancer re21 search gap. 

22 (11) Barriers to screening should be minimized 

23 for high-risk men in order to catch asymptomatic 

24 prostate cancer before it metastasizes and the sur25 vival rate is dramatically reduced. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
4 

•S 2821 IS

1 (12) The cost of treating metastatic prostate 

2 cancer in the United States health care system is 

3 hundreds of millions of dollars more annually than 

4 the cost of treating localized, early-stage cancer. 

5 SEC. 3. REQUIREMENT FOR GROUP HEALTH PLANS AND 

6 HEALTH INSURANCE ISSUERS OFFERING 

7 GROUP OR INDIVIDUAL HEALTH INSURANCE 

8 COVERAGE TO PROVIDE COVERAGE FOR 

9 PROSTATE CANCER SCREENINGS WITHOUT 

10 IMPOSITION OF COST-SHARING REQUIRE11 MENTS. 

12 (a) IN GENERAL.—Section 2713(a) of the Public 

13 Health Service Act (42 U.S.C. 300gg–13(a)) is amend14 ed— 

15 (1) by striking paragraph (5); 

16 (2) by redesignating paragraphs (1) through 

17 (4) as subparagraphs (A) through (D), respectively, 

18 and adjusting the margins accordingly; 

19 (3) by striking ‘‘(a) IN GENERAL—A group 

20 health’’ and inserting the following: 

21 ‘‘(a) COVERAGE OF PREVENTIVE HEALTH SERV22 ICES.— 

23 ‘‘(1) IN GENERAL.—A group health’’; 

24 (4) in subparagraph (B), as so redesignated, by 

25 striking ‘‘; and’’ and inserting a semicolon; 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
5 

•S 2821 IS

1 (5) in subparagraph (C), as so redesignated, by 

2 striking the period and inserting a semicolon; 

3 (6) in subparagraph (D), as so redesignated— 

4 (A) by striking ‘‘paragraph (1)’’ and in5 serting ‘‘subparagraph (A)’’; and 

6 (B) by striking the period and inserting ‘‘; 

7 and’’; 

8 (7) by inserting after subparagraph (D), as so 

9 redesignated, the following: 

10 ‘‘(E) with respect to men who are age 40 

11 and over and are at high risk of developing 

12 prostate cancer (including African-American 

13 men and men with a family history of prostate 

14 cancer (as defined in paragraph (2))), such ad15 ditional evidence-based preventive care and 

16 screenings not described in subparagraph (A) 

17 for prostate cancer.’’; and 

18 (8) by striking the flush text at the end and in19 serting the following: 

20 ‘‘(2) MEN WITH A FAMILY HISTORY OF PROS21 TATE CANCER DEFINED.—For purposes of para22 graph (1)(E), the term ‘men with a family history 

23 of prostate cancer’ means men who have a first-de24 gree relative— 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
6 

•S 2821 IS

1 ‘‘(A) who was diagnosed with prostate can2 cer; 

3 ‘‘(B) who developed prostate cancer; 

4 ‘‘(C) whose death was a result of prostate 

5 cancer; 

6 ‘‘(D) who have been diagnosed with a can7 cer known to be associated with increased risk 

8 of prostate cancer; or 

9 ‘‘(E) who has a genetic alteration known to 

10 be associated with increased risk of prostate 

11 cancer. 

12 ‘‘(3) CLARIFICATION REGARDING BREAST CAN13 CER SCREENING, MAMMOGRAPHY, AND PREVENTION

14 RECOMMENDATIONS.—For the purposes of this Act, 

15 and for the purposes of any other provision of law, 

16 the current recommendations of the United States 

17 Preventive Service Task Force regarding breast can18 cer screening, mammography, and prevention shall 

19 be considered the most current other than those 

20 issued in or around November 2009. 

21 ‘‘(4) RULE OF CONSTRUCTION.—Nothing in 

22 this subsection shall be construed to prohibit a plan 

23 or issuer from providing coverage for services in ad24 dition to those recommended by the United States 

25 Preventive Services Task Force or to deny coverage 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
7 

•S 2821 IS

1 for services that are not recommended by such Task 

2 Force.’’. 

3 (b) EFFECTIVE DATE.—The amendments made by 

4 subsection (a) shall apply with respect to plan years begin5 ning on or after January 1, 2024. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB